Overcoming Resistance in a BRAF V600e–Mutant Adenocarcinoma of the Lung

T. Schmid; M. Buess

doi:10.3747/co.25.3936

You are currently viewing a new version of our website. To view the old version click .

Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Case Report

1 June 2018

Overcoming Resistance in a BRAF V600e–Mutant Adenocarcinoma of the Lung

and

Department of Oncology, St. Claraspital, Kleinriehenstrasse 30, Basel 4016, Switzerland

Author to whom correspondence should be addressed.

Curr. Oncol.2018, 25(3), 217-219;https://doi.org/10.3747/co.25.3936

Version Notes

Order Reprints

Abstract

We report on a patient with an adenocarcinoma of the lung harbouring a BRAF V600E mutation who benefited from combination therapy with dabrafenib–trametinib after developing resistance to vemurafenib. To our knowledge, our report shows, for the first time, that combination therapy with dabrafenib–trametinib can overcome vemurafenib resistance in a BRAF V600E–mutated adenocarcinoma of the lung.

Keywords:

adenocarcinoma; BRAF; MEK; targeted therapy; acquired resistance; non-small-cell lung cancer; dabrafenib; trametinib

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

Harmonization of PD-L1 Testing in Oncology: A Canadian Pathology Perspective

Anastomosing Hemangioma of the Kidney: Radiologic and Pathologic Distinctions of a Kidney Cancer Mimic